• News and Announcements


    Vigene Biosciences Ranks 81st on the 2018 Inc. 5000.

    ROCKVILLE, Md., August 15, 2018 Inc. magazine today revealed that Vigene Biosciences is No. 81 on its 37th annual Inc. 5000, the most prestigious ranking of the nation's fastest-growing private companies. The list represents a unique look at the most successful companies within the American economy's most dynamic segment—its independent small businesses. Microsoft, Dell, Domino's Pizza, Pandora, LinkedIn, Yelp, Zillow, and many other well-known names gained their first national exposure as honorees on the Inc. 5000. Read More

    .

    Vigene Biosciences Named Emerging Growth Company of the Year at 2018 Corporate Growth Awards.

    ROCKVILLE, Md., May 29, 2018 Vigene Biosciences, Inc. has been recognized as the 2018 Emerging Growth Company of the Year by ACG National Capital."The Corporate Growth Awards are highly competitive," said Howard Rothman, Corporate Growth Awards Committee Member and Vice President of Wealth Management at UBS Financial Services Inc. "Every year, ACG National Capital receives over a hundred nominations for businesses and deal teams representing a wide variety of different business areas. I am excited to celebrate the success of Vigene for their win and for being the only winner from the biotechnology industry." Read More

    Vigene Biosciences announces partnership with Virovek to make high yield cGMP AAV production technology accessible and affordable.

    ROCKVILLE, Md., Apr. 16, 2018 Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development, announced today that the company is partnering with Virovek to utlize its proprietary AAV Production Technology, BAC-to-AAV, in AAV GMP productions. This technology utilizes the baculovirus expression system to produce AAV vectors in insect cells under serum-free condition. AAV produced from BAC-to-AAV has been proven to infect and transduce a myriad of mammalian cells in vivo and in vitro. Read More

    Vigene Biosciences Partners with The Michael J. Fox Foundation to Distribute Alpha-synuclein Knockdown Viral Vectors for Parkinson’s Disease Research

    ROCKVILLE, Md., Nov. 7, 2017  Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development, today announced a collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) for AAV repository and domestic production. Viral vectors to knockdown mouse or human alpha-synuclein (aSyn) will be made available for purchase in early 2018. Read More

    Vigene Biosciences and Mila’s Miracle Foundation announce partnership on Gene therapy for CLN7 Batten Disease

    ROCKVILLE, Md., Nov. 1, 2017 Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for clinical and research-grade viral vector production and development, announces a partnership with Mila’s Miracle Foundation (MMF) to manufacture recombinant adeno-associated virus (rAAV) needed to advance clinical trials for CLN7 Batten Disease. Read More

    Vigene Biosciences Acquires the cGMP Manufacturing Facility and Assets of Omnia Biologics

    ROCKVILLE, Md., Nov. 29, 2016 /PRNewswire/ -- Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development, announced today that the company has entered into a definitive agreement to acquire the assets of Omnia Biologics, Inc. (Omnia), including Omnia's cGMP facility and equipment. Read More